Welcome to our dedicated page for Nexentis Technologies news (Ticker: NXTS), a resource for investors and traders seeking the latest updates and insights on Nexentis Technologies stock.
Nexentis Technologies Inc. reports company developments tied to mitochondrial drug discovery, solar energy asset investments, and its controlled interest in Save Foods Ltd. News about the company includes updates from MitoCareX Bio Ltd., including the MITOLINE™ algorithm platform for SLC25 mitochondrial carrier protein analysis and 3D homology modeling.
Recurring Nexentis news also covers public-company capital actions, Nasdaq trading matters, and the company’s mix of biotechnology, Ready to Build solar assets, and post-harvest treatment technology exposure through Save Foods.
Nexentis (NASDAQ:NXTS) reported that its subsidiary MitoCareX Bio has achieved its first drug discovery milestone since acquisition: an optimized hit molecule with substantially improved pharmaceutical properties versus the initial hit compound.
The molecule was generated using the proprietary MITOLINE® algorithm, which models mitochondrial SLC25 carrier proteins and supports progression toward a lead molecule and pre-clinical development for hard-to-treat cancers and inflammatory metabolic diseases.
Nexentis Technologies (NASDAQ:NXTS) announced that subsidiary MitoCareX Bio achieved its first drug discovery milestone since acquisition: an optimized hit molecule with substantially improved pharmaceutical properties versus the initial hit.
The MITOLINE® algorithm generated 3D structural models of a mitochondrial SLC25 carrier protein, enabling discovery of a novel small molecule candidate aimed at hard-to-treat cancers and inflammatory metabolic diseases and supporting progress toward pre-clinical development.
Nexentis Technologies (NASDAQ: NXTS) announced that wholly owned subsidiary MitoCareX received U.S. trademark registration for its algorithm platform MITOLINE™ on May 5, 2026. MITOLINE is a proprietary sequence analysis and alignment algorithm for SLC25 mitochondrial carrier proteins that supports 3D homology modeling and virtual screening.
The platform underpins MitoCareX’s cloud discovery engine for identifying small molecule scaffolds and validating candidates in mitochondrial and cellular in vitro systems.
Nexentis Technologies (NASDAQ: NXTS) launched a new corporate website on March 13, 2026, following its rebrand from N2OFF and the October 2025 acquisition of MitoCareX Bio.
The site showcases the proprietary MITOLINE™ AI-driven discovery engine, MitoCareX integration targeting the mitochondrial SLC25 family, and non-core solar investments under the Ready-to-Build (RTB) model.